Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur

S. S. Rodionova; A. I. Snetkov; A. D. Akinshina; I. V. Bulycheva; A. N. Torgashin; T. A. Grebennikova; Zh. E. Belaya; Е. M. Agafonova; N. V. Toroptsova; O. A. Nikitinskaya

doi:10.14412/1995-4484-2019-708-712

Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur

S. S. Rodionova, A. I. Snetkov, A. D. Akinshina, I. V. Bulycheva, A. N. Torgashin, T. A. Grebennikova, Zh. E. Belaya, Е. M. Agafonova, N. V. Toroptsova, O. A. Nikitinskaya

https://doi.org/10.14412/1995-4484-2019-708-712

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Tumor-induced hypophosphatemic osteomalacia is a rare disease and its diagnosis presents certain difficulties. This is primarily due to small tumor size and to the absence of local clinical symptoms. Adult-onset newly diagnosed hypophosphatemia concurrent with hyperphosphaturia is a sign of tumor-induced hypophosphatemic osteomalacia. The paper describes a female patient with fibroblast growth factor 23-secreting tumor of the upper third of the femur. After tumor removal, pharmacological treatment involves prescribing calcium supplements and active vitamin D metabolite until normal bone mineral density is restored.

Keywords

osteomalacia, fibroblast growth factor 23, tumor, hypophosphatemia, metabolic diseases

About the Authors

S. S. Rodionova

N.N. Priorov National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia
Russian Federation

10, Priorov St., Moscow 127299

Competing Interests: not

A. I. Snetkov

N.N. Priorov National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia
Russian Federation

10, Priorov St., Moscow 127299

Competing Interests:

not

A. D. Akinshina

N.N. Priorov National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia
Russian Federation

10, Priorov St., Moscow 127299

Competing Interests: not

I. V. Bulycheva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation

23, Kashirskoye Shosse, Moscow 115478

Competing Interests: not

A. N. Torgashin

N.N. Priorov National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia
Russian Federation

10, Priorov St., Moscow 127299

Competing Interests: not

T. A. Grebennikova

National Medical Research Center of Endocrinology, Ministry of Health of Russia
Russian Federation

11, Dmitry Ulyanov St., Moscow 117036

Competing Interests: not

Zh. E. Belaya

National Medical Research Center of Endocrinology, Ministry of Health of Russia
Russian Federation

11, Dmitry Ulyanov St., Moscow 117036

Competing Interests: not

Е. M. Agafonova

V.A. Nasonova Research Institute of Rheumatology
Russian Federation

34A, Kashirskoye Shosse, Moscow 115522

Competing Interests: not

N. V. Toroptsova

V.A. Nasonova Research Institute of Rheumatology
Russian Federation

34A, Kashirskoye Shosse, Moscow 115522

Competing Interests: not

O. A. Nikitinskaya

V.A. Nasonova Research Institute of Rheumatology
Russian Federation

34A, Kashirskoye Shosse, Moscow 115522

Competing Interests: not

References

1. Niemeier T, Leddy L, Bolster M. Insufficiency fracture associated with oncogenic osteomalacia. JCR. 2013 Jan;19(1):38-42. doi: 10.1097/RHU.0b013e31827cd112

2. Sundaram M, McCarthy EF. Oncogenic osteomalacia. Skeletal Radiol. 2000 Jan;29:117-24. doi: 10.1007/s002560050581

3. Lewiecki EM, Urig EJ, Williams RC Jr. Tumor-induced osteomalacia: lessons learned. Arthritis Rheum. 2008;(58):773-7. doi: 10.1002/art.23278

4. Teasell RW, Shapiro AP. Misdiagnosis of conversion disorders. Am JPhys MedRehabil. 2002;(81):236-40. doi: 10.1097/00002060-200203000-00015

5. Chong WH, Molinolo AA, Chen CC, et al. Tumor-induce osteomalacia. Endocr Relat Cancer. 2011;(18):53-77. doi: 10.1530/ERC-11-0006

6. Dobronravov VA. A modern look at the pathophysiology of secondary hyperparathyroidism: the role of fibroblast growth factor 23. Nefrologiya. 2011;(4):11-20 (In Russ.).

7. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345-8. doi: 10.1038/81664

8. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor inducedosteomalacia. Proc Natl Acad Sci USA. 2001;98:6500-5. doi: 10.1073/pnas.101545198

9. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity offi-broblast growth factor 23 measurements in tumor-inducedosteo-malacia. J Clin Endocrinol Metab. 2006;91:2055-61. doi: 10.1210/jc.2005-2105

10. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of esenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359:761-3. doi: 10.1016/S0140-6736(02)07846-7

11. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord. 2001;2:175-86. doi: 10.1023/A:1010006811394

12. Shane E, Parisien M, Henderson JE, et al. Tumor-induced osteo-malacia:clinical and basic studies. J Bone Miner Res. 1997;12:1502-11. doi: 10.1359/jbmr.1997.12.9.1502

Review

For citations:

Rodionova S.S., Snetkov A.I., Akinshina A.D., Bulycheva I.V., Torgashin A.N., Grebennikova T.A., Belaya Zh.E., Agafonova Е.M., Toroptsova N.V., Nikitinskaya O.A. Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur. Rheumatology Science and Practice. 2019;57(6):708-712. (In Russ.) https://doi.org/10.14412/1995-4484-2019-708-712

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Rheumatology Science and Practice

Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy